Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

"Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

"I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

Houston can expect the new vaccine in the next week. WPA Pool / Getty Images

Here's when Houston can expect the Johnson & Johnson COVID-19 vaccine

coming soon

Texas can expect to receive the first 200,000 doses of the coveted Johnson & Johnson COVID-19 vaccine this week. The company announced that it has started the rollout process on March 1 — after the FDA approved its Emergency Use Authorization.

The Center for Disease Control gave the developer, Janssen Pharmaceutical, the final greenlight Sunday, February 28.

What does that mean for Houston? Mayor Sylvester Turner said the Houston Health Department is also anticipated to be on the list to receive Johnson & Johnson doses within the next seven days.

"That will be a game changer," Turner said at an event on February 28 afternoon. "There will be more vaccines available in a shorter period of time. We anticipate that we will probably get a shipment in sometime this week that will add to the Pfizer [doses] that we are using at NRG."

Turner said other clinics with the Houston Health Department have been administering the Moderna vaccine.

The Johnson & Johnson vaccine does have noticeable differences from the Pfizer and Moderna vaccines, experts said.

The MRNA vaccines each require two shots which are usually delivered weeks apart and stored in freezers. The Johnson & Johnson vaccine is a single shot that can be stored in a refrigerator for up to three months at 35 to 46 degrees.

However, Johnson & Johnson does not have as much of the COVID-19 vaccine produced as originally anticipated. ABC13 confirmed 3.9 million doses will be shipped out across the country this week. Johnson & Johnson announced roughly an additional 16 million doses by the end of the month.

"In the next few weeks, it won't have much of any impact because they only have at least three or four million doses available, and that's disappointing news," says Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. "In the longer term, over the next few months, it's really important because we need a greater vaccine supply. We are not going to get there with the two MRNA vaccines. We need probably up to five different vaccines in order to vaccinate the American people."

Recently, there has been a decline in COVID-19 hospitalizations and COVID-19 cases reported statewide. As of Sunday, about 5,700 Texans are in the hospital due to COVID-19, which is half the number of hospitalization in the beginning of the month.

Infectious disease epidemiologist Dr. Catherine Troisi says it's important for people to not let their guard down and that people should get tested if they have been in a high-exposure situation, or if they have been in direct contact with someone who has tested positive.

"Get vaccinated, don't worry about what vaccine it is," Dr. Troisi notes. "It's true that unfortunately there are not as many doses right now of the Johnson & Johnson vaccine as we have hoped, but the company is saying that by the end of June, they will have a 100 million doses, and that's into 100 million people because you don't need two doses.

"So, we expect to have 600 million doses of the other two vaccines, that's 300 million people," she continues. "That should be enough for everyone who wants the vaccine to be able to get it. With one caveat and that is as of right now we do not have a vaccine for children under age 16. Those trials are going on, hopefully as we go throughout the year there will be a vaccine licensed to 12 year-olds and then maybe going down to 8 years or older."

For more details on the Johnson & Johnson vaccine rollout, visit the FDA's website.

---

This article originally ran on CultureMap. For more on this story, visit our news partner ABC13.

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

TMC names former JLABS leader as the director of the Innovation Institute

taking control

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice University's edtech company receives $90M to lead NSF research hub

major collaboration

An educational technology company based out of Rice University has received $90 million to create and lead a research and development hub for inclusive learning and education research. It's the largest research award in the history of the university.

OpenStax received the grant funding from the U.S. National Science Foundation for a five-year project create the R&D hub called SafeInsights, which "will enable extensive, long-term research on the predictors of effective learning while protecting student privacy," reads a news release from Rice. It's the NSF's largest single investment commitment to national sale education R&D infrastructure.

“We are thrilled to announce an investment of $90 million in SafeInsights, marking a significant step forward in our commitment to advancing scientific research in STEM education,” NSF Director Sethuraman Panchanathan says in the release. “There is an urgent need for research-informed strategies capable of transforming educational systems, empowering our nation’s workforce and propelling discoveries in the science of learning.

"By investing in cutting-edge infrastructure and fostering collaboration among researchers and educators, we are paving the way for transformative discoveries and equitable opportunities for learners across the nation.”

SafeInsights is funded through NSF’s Mid-scale Research Infrastructure-2 (Mid-scale RI-2) program and will act as a central hub for 80 partners and collaborating institutions.

“SafeInsights represents a pivotal moment for Rice University and a testament to our nation’s commitment to educational research,” Rice President Reginald DesRoches adds. “It will accelerate student learning through studies that result in more innovative, evidence-based tools and practices.”

Richard Baraniuk, who founded OpenStax and is a Rice professor, will lead SafeInsights. He says he hopes the initiative will allow progress to be made for students learning in various contexts.

“Learning is complex," Baraniuk says in the release. "Research can tackle this complexity and help get the right tools into the hands of educators and students, but to do so, we need reliable information on how students learn. Just as progress in health care research sparked stunning advances in personalized medicine, we need similar precision in education to support all students, particularly those from underrepresented and low-income backgrounds.”

OpenStax awarded $90M to lead NSF research hub for transformational learning and education researchwww.youtube.com

2 Houston startups selected by US military for geothermal projects

hot new recruits

Two clean energy companies in Houston have been recruited for geothermal projects at U.S. military installations.

Fervo Energy is exploring the potential for a geothermal energy system at Naval Air Station Fallon in Nevada.

Meanwhile, Sage Geosystems is working on an exploratory geothermal project for the Army’s Fort Bliss post in Texas. The Bliss project is the third U.S. Department of Defense geothermal initiative in the Lone Star State.

“Energy resilience for the U.S. military is essential in an increasingly digital and electric world, and we are pleased to help the U.S. Army and [the Defense Innovation Unit] to support energy resilience at Fort Bliss,” Cindy Taff, CEO of Sage, says in a news release.

A spokeswoman for Fervo declined to comment.

Andy Sabin, director of the Navy’s Geothermal Program Office, says in a military news release that previous geothermal exploration efforts indicate the Fallon facility “is ideally suited for enhanced geothermal systems to be deployed onsite.”

As for the Fort Bliss project, Michael Jones, a project director in the Army Office of Energy Initiatives, says it’ll combine geothermal technology with innovations from the oil and gas sector.

“This initiative adds to the momentum of Texas as a leader in the ‘geothermal anywhere’ revolution, leveraging the robust oil and gas industry profile in the state,” says Ken Wisian, associate director of the Environmental Division at the U.S. Bureau of Economic Geology.

The Department of Defense kicked off its geothermal initiative in September 2023. Specifically, the Army, Navy, and Defense Innovation Unit launched four exploratory geothermal projects at three U.S. military installations.

One of the three installations is the Air Force’s Joint Base San Antonio. Canada-based geothermal company Eavor is leading the San Antonio project.

Another geothermal company, Atlanta-based Teverra, was tapped for an exploratory geothermal project at the Army’s Fort Wainwright in Alaska. Teverra maintains an office in Houston.

------

This article originally ran on EnergyCapital.